Sequoia Sciences has an unparalleled collection of structurally diverse natural product compounds isolated from plants.  From this collection, Sequoia has identified compounds that may potentially provide new and alternative treatments for acute bacterial infections and chronic infections involving bacterial biofilms. Based upon these results, Sequoia Sciences is embarking on preclinical development programs with the goals of addressing the unmet medical needs for the treatment of lung infections in Cystic Fibrosis patients and chronic urinary tract infections. These programs consist of small molecules targeting gram-positive and gram-negative infections and vaccines for the treatment and prevention of chronic urinary tract infections. To this purpose, we are engaged in collaborations with other laboratories and universities.  Our goal is to improve the quality of life for those individuals significantly affected by acute bacterial infections and chronic infections involving bacterial biofilms.

Upcoming Presentations | See All

Dec. 2009: Sequoia presents at the Royal Pharmaceutical Society of Great Britian meeting, "The Role of Naural Products in Drug Discovery and Development in the New Millennium"

Feb. 2010: Sequoia presents at the Royal Society of Chemistry meeting, "Structure 2010, Advances in Structure Elucidation"

Recent Publications | See All

Jan. 2010: Starks, C.; Williams, R.B.; Goering, M.G.; O'Neil-Johnson, M.; Norman, V.L.; Hu, J.F.; Garo, E.; Hough, B.; Rice, S.M.; Eldridge, G.R. Antibacterial Clerodane Diterpenes from Solidago vigaurea. Phytochemistry, 2010, 71, 104-109